Difference between revisions of "Retaspimycin (IPI-504)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 10: | Line 10: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' IPI-504 |
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Hsp90 inhibitors]] | [[Category:Hsp90 inhibitors]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 00:05, 16 April 2021
General information
Class/mechanism: Hsp90 (heat shock protein 90) inhibitor. Hsp90 is a molecular chaperone that stabilizes various cellular proteins, such as growth factor receptors and molecules involved in signal transduction. Hsp90 is overexpressed in cancer cells and may help to stabilize less stable proteins produced by DNA mutations. By inhibiting Hsp90, retaspimycin may accelerate degradation of growth factors and increase the sensitivity of cancer cells to environmental stress, leading to apoptosis of tumor cells.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
No information available.
Also known as
- Code name: IPI-504